Patent Classification

Treatment, Acid Reflux/Heartburn

1. Reduction of heartburn episodes after ingestion of orange juice
    
2. Reduction of heartburn episodes after ingestion of orange juice

Treatment, Acne

1. Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    
2. Topical acne vulgairs medication with a sunscreen
    
3. Method of treating acne
    
4. Treatment of acne using alkonolamine compositions
    
5. Oral composition and method for the treatment of inflammatory cutaneous disorders
    
6. Anti-acne compositions and methods of use
    
7. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris
    
8. Method of treating acne vulgaris and composition
    
9. Methods of increasing the efficacy of peroxides
    
10. Use of dual compartment mixing container for enzyme mixtures useful to treat acne
     
11. Antibiotic/benzoyl peroxide dispenser
     
12. Use of plant extracts for treatment of acne and furuncle
    
    
13. Method for treating acne

Treatment, Addictive Disorders

1. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
    
2. Treatment of addiction and addiction-related behavior using a composition of topiramate
    
3. Treatment of addiction and addiction-related behavior
    
4. Use of pramipexole for the treatment of addictive disorders

Treatment, Adenocarcinomas

1. Use of substance P antagonists in the treatment of the adenocarcinomas

Treatment, African/Viral,  Hemorrhagic Fever/Ebola

1. Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
    
2. Ebola virion proteins expressed from venezuelan equine encephalitis (VEE) virus replicons
    
3. Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
    
4. Immunization for ebola virus infection
    
5. Method of treating viral hemorrhagic fever
    
6. Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever

Treatment, AIDS/HIV

1. Method for measuring resistance of a patient HIV-2 to protease inhibitors
    
2. HIV-1 DNA fragments that hybridize to genomic HIV-1DNA
    
3. Synergistic HIV/AIDS and/or immune disease phyto-nutraceutical composition
    
4. Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
    
5. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
    
6. Fusion proteins of non-attenuated HIV regulatory/accessory proteins
    
7. Methods and compositions for impairing multiplication of HIV-1
    
8. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
    
9. Method of screening for drug hypersensitivity reaction
    
10. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
     
11. Non-M, non-O HIV-1 strains, fragments and uses
     
12. Antigens encoded by alternative reading frames from pathogenic viruses
     
13. Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
     
14. HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides
     
15. Multimerization of HIV-1 Vif protein as a therapeutic target 
     
16. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
     
17. DNA vaccine compositions and methods of use
     
18. Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
     
19. Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins
     
20. Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
     
21. Single cell analysis of HIV replication capacity and drug resistance
     
22. Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
     
23. Cellular genes regulated by HIV-1 infection and methods of use thereof
     
24. Core structure of gp41 from the HIV envelope glycoprotein
     
25. Human immunodeficiency virus (HIV) nucleotide sequences
     
26. Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
     
27. Drug for AIDS treatment
     
28. Cyclic peptides and aids vaccines
     
29. Amplification of HIV-1 gag sequences for detection of sequences associated with drug-resistance mutations
     
30. Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
     
31. Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
     
32. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1(INI1)/hSNF5
     
33. Compositions and methods for eliciting immune or anti-infective responses
     
34. Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
     
35. Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients
     
36. GB virus C and methods of treating viral infections
     
37. Cellular genes regulated by HIV-1 infection and methods of use thereof
     
38. Antigenic composition comprising an HIV gag or env polypeptide
     
39. Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
     
40. Variant Tat proteins and methods for use thereof
     
41. Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes
     
42. Method for mutation detection in HIV-1 using pol sequencing
     
43. Methods for treating HIV infected subjects
     
44. Peptide inhibitors of HIV entry
     
45. Expressing gp140 fragment of primary HIV-1 isolate
     
46. Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities
     
47. RANTES mutants and therapeutic applications thereof
     
48. Compositions and methods for treating retroviral infections
     
49. CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
     
50. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
     
51. Pharmaceutical formulations
     
52. Compositions and methods for inhibition of HIV-1 infection
     
53. Sustained release beadlets containing stavudine
     
54. Methods of identifying g-couple receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
     
55. Methods for inhibiting HIV-1 infection
     
56. HIV-specific cytotoxic T-cell responses
     
57. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
     
58. Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
     
59. Combined therapy for treatment of HIV infection
     
60. Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
     
61. Method of treatment of human immunodeficiency diseases
     
62. Detection of HIV
     
63. Rhabdoviruses with reengineered coats
     
64. Method of inducing the production of antibodies to HIV
     
65. Method for determining prognosis of HIV infected individuals
     
66. HIV vaccine
     
67. Methods for inhibiting HIV-1 infection
     
68. Synthetic peptides useful in biological assays for detecting infections caused by group O HIV-1 viruses
     
69. Combination antiviral and interleukin-2 therapy for HIV infection
     
70. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
     
71. Non-M, non-O HIV-1 strains, fragments and uses
     
72. Treatment of lipodystrophy
     
73. Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
     
74. Selective destruction of cells infected with human immunodeficiency virus
     
75. Antiviral composition comprising glycine amide
     
76. Modified HIV-1gag p17 peptide and immunogenic composition
     
77. Human monoclonal antibody against coreceptors for human immunodeficiency virus
     
78. Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
     
79. Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80
     
80. Human immunodeficiency virus immunogenic composition
     
81. Human immunodeficiency virus type 2 (HIV-2) env polypeptide and diagnostic assays
     
82. Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same
     
83. Method for producing recombinant cells for detecting HIV
     
84. Pharmaceutical being used for treating HIV infection, the composition and uses thereof
     
85. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
     
86. Methods of assessing HIV integrase inhibitor therapy
     
87. Amplification of HIV-1 gag sequences for detection of sequences associated with drug-resistance mutations
     
88. Inhibitors for RNA viruses
     
89. Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses
     
90. Stabilized soluble glycoprotein trimers
     
91. HIV related peptides
     
92. Methods of treating HIV infected subjects
     
93. Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor
     
94. Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
     
95. Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
     
96. Methods of monitoring HIV drug resistance
     
97. Method of amplifying or detecting HIV-1 RNA
     
98. Inhibition of retrovirus infection
     
99. Kits for detecting HIV-2
     
100. Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations
      
101. Cloning and expression of HTLV-III DNA
      
102. Process for making antifusogenic fusion peptides that form inclusion bodies
      
103. CD4-independent HIV envelope proteins as vaccines and therapeutics
      
104. Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
      
105. Inhibitors of HIV membrane fusion
      
106. .beta.-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
      
107. Monoclonal antibodies to human immunodeficiency virus and uses thereof
      
108. HIV envelopolype peptides
      
109. Nef-attachable protein
      
110. Methods for treating HIV-infected patients by the administration of GM-CSF and a protease inhibitor
      
111. Method and kit for detecting resistance to antiviral drugs
      
112. Adenovirus carrying gag gene HIV vaccine
      
113. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
      
114. Inhibition of HIV-1 replication by antisense RNA expression
      
115. Methods for diagnosing and treating autoimmune disease
      
116. Indian green mussel (Perna viridis) as a source of anti-HIV activity
      
117. Use of parasitic biological agents for prevention and control of autoimmune diseases
      
118. Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
      
119. Methods of using cyanovirins to inhibit viral infection
      
120. HIV immunogenic compositions and methods
      
121. Treatment of viral infections
      
122. Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
      
123. Immune enhancing agent for treating HIV infected humans
      
124. Stabilized viral envelope proteins and uses thereof
      
125. HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
      
126. Combination therapy for HIV infections
      
127. HIV vaccine
      
128. Compositions and methods for inhibition of HIV-1 infection
      
129. Combination therapy for HIV infection
      
130. Inhibition of HIV replication using soluble Tat peptide analogs
      
131. Compositions and methods for the treatment of viral disorders
      
132. Soluble lymphotoxin-.beta. receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease
      
133. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease
      
134. Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome
      
135. Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
      
136. Method for the development of an HIV vaccine
      
137. Methods for inducing mucosal immune responses
      
138. Selective destruction of cells infected with human immunodeficiency virus
      
139. AIDS prophylactic lubricating composition and devices for its use
      
140. Methods and means for inducing apoptosis by interference in RNA processing
      
141. Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects
      
142. Rantes mutants and therapeutic applications thereof
      
143. Expression of HIV polypeptides and production of virus-like particles
      
144. Delayed progression to aids by a missense allele of the CCR2 gene
      
145. Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
      
146. Methods of therapy for HIV infection
      
147. Drug combination for the treatment of viral diseases
      
148. Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
      
149. Compounds which inhibit HIV replication
      
150. Biodegradable microbicidal vaginal barrier device
      
151. Treatment of autoimmune diseases
      
152. Compositions and methods for preventing transepithelial transmission of HIV
      
153. Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
      
154. Synthetic HIV-2 envelope genes containing modifications that lead to optimized expression in bacteria
      
155. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
      
156. Vaccines comprising synthetic genes
      
157. Invasive bacterial vectors for expressing alphavirus replicons
      
158. Anti-CCR5 antibodies and kits comprising same
      
159. Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
      
160. Compositions for treating autoimmune disease
      
161. Antigentically-marked non-infectious retrovirus-like particles
      
162. Method for treatment of immunodeficiency virus infection
      
163. Killer T cell receptor recognizing human immunodeficiency virus
      
164. Methods for producing an immune response against HIV-1
      
165. Use of HIV protease inhibiting compounds
      
166. Method for the development of an HIV vaccine
      
167. Replication defective HIV vaccine
      
168. Channel forming toxins as antiviral agents
      
169. EIA test using nondenatured HIV antigen for early detection of HIV infection
      
170. Polypeptide having human HIV inhibitory activity, a gene encoding the polypeptide, a method to produce the polypeptide
      
171. Method for control and treatment of acquired immunodeficiency syndrome (AIDS)
      
172. Medicinal herbal composition for treating liver diseases and HIV
      
173. Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
      
174. Methods of treating autoimmune diseases with gp39-specific antibodies
      
175. Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
      
176. Methods of using cyanovirins topically to inhibit viral infection
      
177. CD4-independent HIV envelope proteins as vaccines and therapeutics
      
178. Compositions and methods for the treatment and diagnosis of immune disorders
     
     
179. Viral vectors for use in monitoring HIV drug resistance
     
     
180. Method of treating humans with diseases characterized by high secretion of cytokines from macrophage cells
     
     
181. Materials and methods for treating autoimmune disease
     
     
182. Methods and compositions for impairing multiplication of HIV-1
     
     
183. Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
     
     
184. HIV chemokines
     
     
185. Remedy for autoimmune diseases
     
     
186. Method of treating complications in immunodepressed states resulting from HIV infection
     
     
187. Drug combinations containing AZT
     
     
188. Use of cytokines and mitogens to inhibit pathological immune responses
     
     
189.  Inhibitors of HIV infection
     
     
190. Cloned DNA Sequences Related To The Entire Genomic RNA Of Human Immunodeficiency Virus II (HIV-2), Polypeptides Encoded By These DNA Sequences And Use Of These DNA Clones And Polypeptides In Diagnostic Kits
     
     
191. Treatment of auto-immune diseases by photochemotherapy
     
     
192. Method of treating HIV infection with transdermal gel containing mammalian liver extract
     
     
193. Methods of treating autoimmune diseases with a CD86-specific immunotoxin
     
     
194. Method for preventing HIV-1 infection of CD4+ cells
     
     
195. Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof 
     
     
196. Antiviral composition derived from allium CEPA and therapeutic use thereof
      
197. Method of specifying vaccine components for viral quasispecies
      
     
198. Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome
      
199. Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission
      
     
200. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
      
     
201. HIV envelope polypeptides
      
     
202. Composition and method for prevention of sexually transmitted diseases, including aids
      
     
203. Antibodies directed against binding associated epitopes
      
     
204. Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies
      
     
205. Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
      
     
206. Genetic suppressor elements against human immunodeficiency virus
      
     
207. Melanins with improved ability to inhibit HIV replication
      
     
208. Nucleic acids containing modified human immunodeficiency virus genomes devoid of long terminal repeats encoding non-infectious, replication-deficient, immunogenic retrovirus-like particles
      
     
209. Pathogen-targeted biocatalysts
      
     
210. Methods and compositions for inhibition of viral replication
      
     
211. Azaftig, a proteoglycan for monitoring cachexia and for control of obesity
      
     
212. Chimeric viral proteins
      
     
213. HIV-vaccines
      
     
214. Prophylaxis and therapy of acquired immunodeficiency syndrome
      
     
215. Immunogenic compositions comprising dimeric forms of the human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) envelope glycoproteins
      
     
216. Peptides that block viral infectivity and methods of use thereof
      
     
217. Use of magnesium based products for the treatment or prophylaxis of autoimmune diseases
      
     
218. Method of using mouse model for evaluation of HIV vaccines
      
     
219. Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV
      
     
220. Method for preventing sexually transmitted diseases
      
     
221. Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
      
     
222. Methods to inhibit replication of infective virus
      
     
223. Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients
      
     
224. Assays for screening for inhibitors of HIV
      
     
225. Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
      
     
226. Method for delaying the onset of AIDS
      
     
227. Process of determining the efficacy of drug treatment in HIV infected subjects
      
     
228. Method for inducing a systemic immune response to an HIV antigen
      
     
229. Methods and compositions for impairing multiplication of HIV-1
      
     
230. Method for treating hemophilia A and B and AIDS and devices used therein
      
     
231. Injection viral treatment
      
     
232. Use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections
      
     
233. Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
      
     
234. Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers (Patent: 6,068,858)
      
     
235. Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers (Patent: 6,045,829)
      
     
236. HIV envelope polypeptides
      
     
237. Method for preventing sexually transmitted diseases
      
238. Method for treating AIDS

Treatment, Allergy

1. Allergy vaccine composition, production method thereof and use of same in allergy treatment
    
2. Biotype diets system: predicting food allergies by blood type
    
3. Immunostimulatory nucleic acids for the treatment of asthma and allergy
    
4. Feline immunoglobulin E molecules and related methods
    
5. Compositions for treating and/or preventing pollinosis
    
6. Allergen vaccine proteins for the treatment and prevention of allergic diseases
    
7. Methods for deactivating allergens and preventing disease
    
8. Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
    
9. Modified fusion molecules for treatment of allergic disease
    
10. Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
     
11. Vaccine for house dust mite allergen using naked DNA
     
12. Methods using eosinophil-specific apoptosis inducer
     
13. Epitope identification and modification for reduced allergenic activity in proteins targeted for transgenic expression
     
14. Protein variants of naturally occurring allergens
     
15. Method for treating allergic rhinitis without adverse effects
     
16. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-.gamma. secretion and/or treating allergy
     
17. Recombinant allergen with reduced enzymatic activity
     
18. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
     
19. Chimeric IgE polypeptides and host cells
     
20. JTT-1 protein and methods of inhibiting lymphocyte activation
     
21. Anti-allergy composition comprising wood vinegar- or bamboo vinegar-distilled solution
     
22. Antibodies to JTT-1 protein and cells secreting such antibodies
     
23. Feline immunoglobulin E proteins and compositions thereof
     
24. Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions
     
25. Allergy inhibition
     
26. Delivery of antihistamines through an inhalation route
     
27. Animal model for allergic disorders
     
28. Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
     
29. Live vaccines for allergy treatment
     
30. Mast cell surface antigen, DNA thereof, and antibody against the antigen
     
31. Local nasal immunotherapy with allergen strip for allergic rhinitis
     
32. Pollen allergy-related gene 513
     
33. Method for binding basophils and mast cells
     
34. Stabilized antihistamine syrup
     
35. FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
     
36. Proteins producing an altered immunogenic response and methods of making and using the same
     
37. Saliva test for detection of food allergy and intolerance
     
38. Polyclonal antibody composition for treating allergy
     
39. Methods for diagnosis of allergic bronchopulmonary aspergillosis
     
40. Compositions containing both sedative and non-sedative antihistamines
     
41. Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
     
42. Modulation of allergic response
     
43. Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
     
44. Orodispersible tablets containing fexofenadine
     
45. IgE-dependent histamine-releasing factor-binding peptides
     
46. Method for denaturing allergens
     
47. Method for diagnosing immunologic food sensitivity
     
48. Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same
     
49. Pharmaceutical composition against type I allergy and the preparation thereof
     
50. Assay for evaluation of cellular response to allergens
     
51. Herbal remedies for treating allergies and asthma
     
52. Peptide immunogens for vaccination against and treatment of allergy
     
53. Rantes mutants and therapeutic applications thereof
     
54. Compound and method for the prevention and/or the treatment of allergy
     
55. Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
     
56. Methods of preventing or treating allergies
     
57. Allergy treatment method using a rapid immunotherapy protocol
     
58. Natural product composition for decreasing IgE production and treating secondary allergic responses
     
59. Transdermal preparation contacting a loratidine metabolite with antihistaminic activity
    
    
60. Ophthalmic anti-allergy compositions suitable for use with contact lenses
    
    
61. Method for treating allergies
    
    
62. Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen
     
    
63. Prophylaxis of allergic disease
     
    
64. Mineral and vitamin combinations for the treatment of stress and allergies
     
    
65. Pheniramine-containing compositions and method for treating allergic responses
     
    
66. Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients
     
    
67. Symptomatic relief of allergic reactions

Treatment, Altitude Sickness

1. Method for treating acute mountain sickness

Treatment, Alzheimer's/Neurodegenerative Disease

1. Modulators of amyloid aggregation
    
2. Methods for diagnosing a neurodegenerative condition
    
3. Composition comprising the extract of crude drug complex having neuroprotective activity for preventing and treating stroke and neurodegenerative diseases
    
4. Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
    
5. Combined regulation of neural cell production
    
6. Methods for diagnosis of Alzheimer's Disease in blood samples
    
7. Biomarkers for neurodegenerative disorders 
    
8. Human brain carboxypeptidase B antibodies
    
9. Methods of inhibiting amyloid toxicity
    
10. Gene regulation therapy involving ferritin
     
11. Alzheimer model for drug screening
     
12. Anti-amyloid immunogenic compositions, methods and uses
     
13. Methods of investigating, diagnosing, and treating amyloidosis
     
14. Amyloid .beta. gene vaccines
     
15. Conformationally abnormal forms of tau proteins and specific antibodies thereto
     
16. Synthetic immunogenic but non amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits
     
17. Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
     
18. Adenovirus serotype 30 (Ad30)
     
19. Tools for the diagnosis and treatment of Alzheimer's disease
     
20. Methods and compounds for inhibiting amyloid deposits
     
21. Prolactin induced increase in neural stem cell numbers
     
22. Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical PKM activity
     
23. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
     
24. Soluble cyclic analogues of .beta. amyloid peptide
     
25. Humanin, a polypeptide suppressing neuronal death
     
26. Diagnostic method for alzheimer's disease based on holo-transcobalamin II
     
27. Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
     
28. Amyloid .beta.1-6 antigen arrays
     
29. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
30. Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
     
31. Humanized antibodies that recognize beta amyloid peptide
     
32. Methods for therapy of neurodegenerative disease of the brain
     
33. Method for treatment of neurodegenerative diseases and effects of aging
     
34. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
35. Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
     
36. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
37. Methods of treating Alzheimer's disease and other amyloidoses using Hypericum perforatum and derivatives thereof
     
38. IL6RIL6 chimera for the treatment of neurodegenerative diseases
     
39. Method and kit for following neurodegenerative diseases
     
40. Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells
     
41. Treatment of alzheimer's disease
     
42. Controlled release microencapsulated NGF formulation
     
43. Transgenic mice comprising a genomic human tau transgene
     
44. Methods for diagnosing a neurodegenerative condition
     
45. Treatments for neurotoxicity in Alzheimer's Disease
     
46. Targeted retrograde gene delivery to motor neurons
     
47. Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
     
48. Treatments for neurotoxicity in Alzheimer's Disease
     
49. Antibodies to a YYX epitope of a mammalian prion protein
     
50. Prevention and treatment of amyloidogenic disease
     
51. Methods for identifying inhibitors of neuronal degeneration
     
52. Prevention and treatment of amyloidogenic disease
     
53. Prevention and treatment of amyloidogenic disease
     
54. Diagnostic methods for drug screening for Alzheimer's disease
     
55. Emu-based compositions for mental well-being and method of use
     
56. Passive immunization of ASCR for prion disorders
     
57. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
58. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
     
59. Active immunization of AScr for prion disorders
     
60. Serine protease BSSP6
     
61. Passive immunization of Alzheimer's disease
     
62. Active immunization for treatment of alzheimer's disease
     
63. Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
     
64. Method of targeting conjugate molecules to mitochondria
     
65. Purified antigen for Alzheimer's disease and methods of obtaining and using same
     
66. Ocular diagnosis of Alzheimer's Disease
     
67. In vitro ischemia model
     
68. Methods for Alzheimer's Disease treatment and cognitive enhancement
     
69. Detection of alzheimer's amyloid by magnetic resonance imaging
     
70. Methods for therapy of neurodegenerative disease of the brain
     
71. Steroidal sapogenins and their derivatives for treating alzheimer's disease
     
72. Prevention and treatment of amyloidogenic disease
     
73. Model for Alzheimer's disease and other neurodegenerative diseases
     
74. Polynucleotides encoding alzheimer's disease secretase
     
75. Prevention and treatment of amyloidogenic disease
     
76. Transgenic animal and methods
     
77. Passive immunization treatment of Alzheimer's disease
     
78. Alzheimer's disease secretase, APP substrates therefor, and uses therefor
     
79. Method of treatment of neuropsychiatric symptoms in patients with Alzheimer's Disease
     
80. Prevention and treatment of amyloidogenic disease
     
81. Alzheimer's disease secretase, APP substrates therefor, and uses therefor
     
82. Method for selecting a transgenic mouse model of alzheimer's disease
     
83. Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits
     
84. Methods and kits for diagnosing Alzheimer's disease from a blood sample
     
85. Diagnosis of tauopathies
     
86. Assays for inhibitors of neuronal transport of Alzheimer's amyloid precursor protein
     
87. Assay for Alzheimer's disease drug development
     
88. Behavior chemotherapy
     
89. Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
     
90. Memory loss treatment formulation
     
91. Methods for improving brain function using leptin or analogs thereof
     
92. Methods for the prevention or treatment of alzheimer's disease
     
93. Method for screening for drugs useful in inhibition of polymerization of a.beta. and tau peptides
     
94. Methods for determining risk of Alzheimer's disease
     
95. Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
     
96. Use of desoxypeganine in the treatment of Alzheimer's dementia
     
97. Method for increasing the concentration of ascorbic acid in brain tissue of a subject
     
98. Assay for compounds which affect conformationally altered proteins
     
99. Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
     
100. Method for administering insulin-like growth factor to the brain
     
     
101. Method of promoting synthesis of nerve growth factor
     
     
102. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
     
     
103. Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
     
     
104. Composition and methods for inhibiting the formation of brain amyloid deposits
     
     
105. Method for administering fibroblast growth factor to the brain 
     
     
106. Method for administering insulin to the brain
      
     
107. Secretases related to Alzheimer's dementia
      
     
108. Intestinal absorption of nicotine to treat nicotine responsive conditions
      
     
109. Solution containing nicotine